Climb Bio (CLYM) Capital Expenditures (2024 - 2026)
Climb Bio's (CLYM) quarterly Capital Expenditures came in at $1.4 million in Q3 2025, up 9686.67% YoY from $14693.5 in Q3 2024, and up 2078.79% on a QoQ basis from $66000.0 in Q2 2025.
Powered by 
Analysis
Climb Bio (CLYM) Capital Expenditures (2024 - 2026) Analysis & Trends
Climb Bio (CLYM) has 2 years of Capital Expenditures data on file, last reported at $1.4 million in Q3 2025.
- Quarterly Capital Expenditures rose 9686.67% year-over-year to $1.4 million in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 616.19% YoY) and the FY2025 annual result came in at $1.5 million, up 657.0% from the prior year.
- Capital Expenditures rose to $1.4 million in Q3 2025, from $66000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.4 million in Q3 2025 to a low of -$15000.0 in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Climb Bio | 1.18 Bn | 1.18 Bn | - | -304,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -304,000.00 |
| Sep 30, 2025 | 162,000.00 |
| Jun 30, 2025 | 1.34 Mn |
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | 215,000.00 |